MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT05597306Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerrence J Bradley, MD · Acute Myeloid LeukemiaRecruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 19, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly...Merck Sharp & Dohme LLC · Endometrial NeoplasmsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT03978624Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder CancerUNC Lineberger Comprehensive Cancer Center · Bladder CancerActive, not recruitingSNDXCollaboratorMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Mar 25, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02293980A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · ccRCCActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02974738A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Advanced Solid TumorsActive, not recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 12, 2018Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT00825929Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.Radboud University Medical Center · HIV Infections
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT01731353FungiScope - A Global Emerging Fungal Infection RegistryUniversity of Cologne · Invasive Fungal Disease
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT02422381MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Providence Health & Services · Carcinoma, Non-Small-Cell LungActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 9, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02644369Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsUniversity Health Network, Toronto · Squamous Cell Cancer of Head and NeckActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT02734290Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerProvidence Health & Services · Triple Negative Breast CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Aug 21, 2019Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT02779751A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerEli Lilly and Company · Non Small Cell Lung CancerActive, not recruitingLLYLeadMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 3, 2020Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03899857Pembrolizumab for Newly Diagnosed GlioblastomaUniversity of Zurich · Newly Diagnosed GlioblastomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Apr 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT04206813An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination RegimenBoston Medical Center · HPV InfectionActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center · Adenoid Cystic CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04373031Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerProvidence Health & Services · Breast CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 8, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04417166Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · Lymphoma, Extranodal NK-T-CellActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05082259ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabInstitute of Cancer Research, United Kingdom · Advanced CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT05378425A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With PembrolizumabNectin Therapeutics Ltd · CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05467917ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index CasesColumbia University · COVID-19Active, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT05625633Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous WartsWestern Institute for Veterans Research · WartsRecruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT03582475Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine...Jonsson Comprehensive Cancer Center · Bladder Small Cell Neuroendocrine CarcinomaActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT03742245Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerThe Methodist Hospital Research Institute · Breast Cancer MetastaticActive, not recruitingMRKCollaboratorAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03989089Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B MutationUniversity of Malaya · HER2-Negative Breast CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05491226Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and RadiationStephen Shiao · TNBC - Triple-Negative Breast CancerRecruitingMRKCollaboratorINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04393350Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell CarcinomaEmory University · Kidney CancerActive, not recruitingMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 13, 2024Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 56 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.